$EDIT News

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine: Resetting Pipeline Just To Be Second To Market Again

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine Announces Proposed Public Offering

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each

Editas Medicine Launches Public Stock Offering to Raise Capital

Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia

Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates

Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Treatment For Hyperlipidemia At Multiple Upcoming Conferences

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interference